The 42nd Annual Healthcare Conference was held on January 8-11, 2024 in San Francisco, CA. Global industry leaders, fast-growing companies, innovators, and members of the investment community gathered in this premier symposium for the largest and most informative healthcare investment symposium in the industry. Global healthcare industry leaders presented on a series of Themes, market trends, recent innovation and overall outlook for 2024 in the biomedical industry along with intriguing panels discussions.

Singapore bioscience entrepreneurs had a spotlight at the conference with Enterprise Singapore & A*STAR and EDBi showcasing the potential of 24 promising biomedical companies from Singapore.

Singapore biomedical companies and founders had an opportunity to foster valuable collaborations between US and Singapore, and hosted numerous conversations among investors to expand and explore their global capabilities beyond Singapore.  EnterpriseSG team and A*STAR leadership have combined their efforts to invest in pioneering sciences and biomedical frontiers.

The conference showcased Singaporean biomedical companies including;

Auristone Pte Ltd, Aevice Health, AUM Biosciences, Avecris, Axcynsis Therapeutics, BioSyngen, Biorithm, Cerecin, Engine Biosciences, ImmunoScape, HeHealth, KYAN Technologies, Lucence, MediSix Therapeutics, MeshBio, Mirxes, NalaGenetics, Nuevocor, Oncoshot, Respiree, SCG Cell Therapy, Tikva Allocell Pte Ltd, VerImmune. Hellimen Laboratory and more.

Delon Toh, Regional Director at Enterprise Singapore shared on social media that, “The investment climate is significantly more buoyant than in 2023, mirrored by both the literal clear skies and the figurative atmosphere of optimism. In a short span, we witness numerous productive discussions, firm handshakes, and burgeoning interest in our companies. Your participation and engagement with our companies were invaluable. We eagerly anticipate facilitating more groundbreaking partnerships and nurturing lasting relationships”.